BioCentury
ARTICLE | Financial News

AnaptysBio raises $208M following Phase IIa asthma readout

September 26, 2018 5:32 PM UTC

AnaptysBio Inc. (NASDAQ:ANAB) raised $207.8 million late Tuesday through the sale of 2.2 million shares at $94.46 in a follow-on underwritten by Credit Suisse, J.P. Morgan, Jefferies, Cantor, Guggenheim Securities and Wedbush PacGrow.

The financing came a day after AnaptysBio reported interim data from a Phase IIa trial evaluating etokimab (formerly ANB020) to treat severe eosinophilic asthma. A single 300 mg dose of IV etokimab led to placebo-adjusted reductions from baseline in blood eosinophil count of 31% at day two and of 46% at day 64. Etokimab also led to placebo-adjusted improvements in forced expiratory volume in 1 second (FEV1) of 8% at day two and of 11% at day 64...

BCIQ Company Profiles

AnaptysBio Inc.